

# Harlan F Weisman

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/11296608/harlan-f-weisman-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18  
papers

1,716  
citations

12  
h-index

18  
g-index

18  
ext. papers

1,824  
ext. citations

6.8  
avg, IF

3.03  
L-index

#	Paper	IF	Citations
18	Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. <i>Circulation</i> , <b>1998</b> , 97, 1680-8	16.7	254
17	Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. <i>Circulation</i> , <b>1995</b> , 91, 2882-90	16.7	189
16	Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. <i>American Journal of Cardiology</i> , <b>1997</b> , 79, 149-56	3	183
15	Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. <i>Journal of the American College of Cardiology</i> , <b>1997</b> , 30, 149-56	15.1	179
14	Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. <i>Journal of the American College of Cardiology</i> , <b>1997</b> , 30, 149-56	15.1	146
13	Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. <i>American Journal of Cardiology</i> , <b>1995</b> , 75, 559-62	3	140
12	Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. <i>Circulation</i> , <b>1999</b> , 99, 1951-8	16.7	127
11	Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. <i>Annals of the New York Academy of Sciences</i> , <b>1991</b> , 614, 193-213	6.5	121
10	Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. <i>American Journal of Cardiology</i> , <b>1997</b> , 79, 286-91	3	120
9	Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , <b>2001</b> , 37, 2059-65	15.1	115
8	The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. <i>Molecular Immunology</i> , <b>1995</b> , 32, 1271-81	4.3	94
7	Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab. <i>American Heart Journal</i> , <b>2000</b> , 139, 696-703	4.9	39
6	Concept and Clinical Application of Platelet Glycoprotein IIb/IIIa Inhibition with Abciximab (c7E3 Fab; ReoPro) for the Prevention of Acute Ischemic Syndromes. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>1997</b> , 3, 256-266	3.3	6
5	The Evolution of ReoPro <sup>®</sup> Clinical Development <b>2000</b> , 323-346		1
4	Abciximab: The First Platelet Glycoprotein IIb/IIIa Receptor Antagonist <b>1999</b> , 35-71		1
3	Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. An industry perspective on health economics studies. <i>American Heart Journal</i> , <b>1999</b> , 137, S129-32	4.9	1
2	ReoPro Clinical Development: A Case Study <b>2001</b> , 365-380		

- 1 ReoPro Clinical Development: A Case Study 365-380